Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.
Sprechen Sie mit dem Deal Team
SulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.Mehr erfahren
Laboratoire Dazont has been acquired by SBM Company
The shareholders of Laboratoire Dazont have sold the company to SBM Company.Mehr erfahren
Change Financial (ASX:CCA) has raised US$4 million
Change Financial has completed a capital raise to help accelerate product enhancement, repay its debt, provide working capital and cover the costs of the offer.Mehr erfahren